Table 1.
Baseline characteristics of patients enrolled in HCMR.
| Variable | Summary statistic | Valid n (%) |
|---|---|---|
| Age (years) | 49 ± 11 | 2738 (99.4) |
| Male gender | 1953 (71.3) | 2740 (99.5) |
| Race / Ethnicity | 2737 (99.3) | |
| White | 2311 (84.4) | |
| Black | 204 (7.4) | |
| Asian | 205 (7.5) | |
| Other | 18 (0.7) | |
| Hispanic | 60 (2.2) | 2739 (99.4) |
| BMI (kg/m2) | 29.3 ± 5.7 | 2726 (98.9) |
| Family history of HCM | 2722 (98.9) | |
| 1st degree | 600 (22.0) | |
| 2nd degree | 84 (3.1) | |
| Both 1st and 2nd | 228 (8.4) | |
| Comorbidities | ||
| Hypertension | 997 (36.6) | 2726 (99.0) |
| Type II diabetes mellitus | 213 (7.8) | 2726 (99.0) |
| Current smoker | 387 (14.2) | 2724 (98.9) |
| NYHA | 2692 (97.7) | |
| Class I | 1792 (66.6) | |
| Class II | 706 (26.2) | |
| Class III/IV | 194 (7.2) | |
| Other clinical history | ||
| Syncope | 361 (13.2) | 2726 (98.9) |
| Heart failure | 142 (5.2) | 2733 (98.9) |
| Stroke | 76 (2.8) | 2733 (98.9) |
| Nonsustained ventricular tachycardia | 196 (12.0) | 1633 (59.3) |
| Number of runs | 3.2 ± 12.1 | |
| Atrial fibrillation | 2723 (98.8) | |
| Persistent | 77 (2.8) | |
| Paroxysmal | 244 (9.0) | |
| Symptoms at enrollment | ||
| Chest pain | 893 (32.8) | 2726 (98.9) |
| Dyspnea | 1184 (43.4) | 2726 (98.9) |
| Medications at enrollment | ||
| Beta blocker | 1547 (57.0) | 2714 (98.5) |
| Calcium channel blocker | 508 (18.7) | 2714 (98.5) |
| ACE/ARB | 644 (23.7) | 2714 (98.5) |
| Disopyramide | 84 (3.1) | 2714 (98.5) |
| Statins | 741 (27.3) | 2714 (98.5) |
| Diuretic | 314 (11.6) | 2714 (98.5) |
| Oral anticoagulant | 251 (9.2) | 2714 (98.5) |
| Oral antiplatelet agent | 431 (15.8) | 2714 (98.5) |
Summary statistics are mean ± 1 standard deviation for continuous variables; n (%) for categorical variables.
Summary statistics based on non-missing values (Valid n) of total analyzed: 2755